x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma"s top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

science life sciences

All Episodes

00:10:43

Thoughtful Tech: How Removing Technological Burdens...

BioSpace ·

2025/11/06

This conversation features insights from Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII. Our guests continue their discussion on how autoinjectors and smart technologies can be integrated into clinical trials in a way that isn’t problematic or burdensome for patients, particularly for patients that may not be tech savvy. They discuss that by focusing on patient experience, clinical trials can increase engagement and compliance.This episode is

en

00:26:26

Pfizer and Novo Battle Over Metsera, Tidmarsh Fights...

BioSpace ·

2025/11/05

Many of the top stories of 2025 are currently being written. We’re on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out over the right to acquire glittery obesity startup Metsera. In the latest development, Pfizer raised its original bid of around $7.27 billion to about $8.1 billion on Monday—only to be usurped again by the indefatigable Novo, which upped its own bid to a cool $10 billion. Meanwhile, the unprecedented drama in the uppermost ranks of the

en

00:14:15

Innovation, Resilience, and the Future of Global...

BioSpace ·

2025/10/30

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how China, historically focused on manufacturing, is increasingly becoming an innovation leader, particularly in pharmaceuticals. Ultimately, balanced strategies involve domestic capacity investments coupled with global collaboration.This episode is presented in partnership with Element Materials Technology.HostsJennifer Smith-Parker, Director of Insights, BioSpaceLori Ellis, Head of Insights, BioSpaceGuestsDr

en

00:26:36

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped...

BioSpace ·

2025/10/29

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That’s the second biggest buy of the year after Johnson & Johnson’s January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis’

en

00:08:59

How Supply Chain Turbulence is Reshaping Biotech...

BioSpace ·

2025/10/23

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney how in light of economic uncertainty, small biotechs can turn to international harmonization standards as a stable template. U.S. tariffs are redefining competitiveness in manufacturing nations like India, China, and other parts of Asia, with China emerging as a global innovator.This episode is presented in partnership with Element Materials Technology.HostsJennifer Smith-Parker, Director of Insights, BioSpaceLori Ellis,

en

00:31:24

Novo Board Upended, ESMO Excitement, FDA Awards,...

BioSpace ·

2025/10/22

Novo Nordisk dominated the news cycle this week, with more leadership changes as the Novo Foundation replaced the company’s board, which will now be headed by former CEO Lars Rebien Sørensen. Meanwhile, President Donald Trump promised last week that Novo’s Ozempic will cost about $150 when he and Centers for Medicare & Medicaid Services Administrator Mehmet Oz are done negotiating, though Oz clarified that said negotiations have not yet begun. Over in Berlin, the 2025 European Society for

en

00:13:35

Cost Control to Capability Building: Rethinking...

BioSpace ·

2025/10/21

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospitals and universities to manufacturers and investors — are rethinking their strategies amid global supply chain disruption.The conversation highlights both immediate operational responses and long-term structural shifts shaping a more resilient, agile, and locally grounded ecosystem, especially in light of U.S. tariffs.This episode is presented in

en

00:14:05

Work Smart, Build Trust: Connecting Technology,...

BioSpace ·

2025/10/16

This episode continues the discussion with Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, as they dive into the nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.In this conversation they focus on supporting decentralized clinical studies and how connected technology can improve patient compliance, trust and cleaner data processing.This episode is presented in partnership with ⁠PII⁠.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori

en

00:27:45

Q3 Earnings Are Here, Novo Ditches Cell Therapy but...

BioSpace ·

2025/10/15

Johnson & Johnson kicked off Q3 earnings season on Tuesday with the announcement that it is splitting its orthopedics and medtech operations and that it has yet to reach a drug pricing deal with the White House, though CEO Joaquin Duato did say those discussions are ongoing. In advance of its Nov. 5 earnings call, Novo Nordisk, under the direction of new CEO Maziar Mike Doustdar, has been busy making moves, doubling down on MASH last week with its $5.2 billion buy of Akero. Then this week, Novo

en

00:11:10

Bonus: Q3 2025 Job Market Update

BioSpace ·

2025/10/14

In this discussion, BioSpace’s vice president of marketing ⁠⁠Chantal Dresner⁠⁠ and careers editor ⁠⁠Angela Gabriel⁠⁠ take a look at job market performance in the second quarter of 2025.They discuss biotech and pharma job posting trends, wider U.S. employment data, the new $100,000 H-1B visa fees and more.Want to receive our latest quarterly job market reports as soon as they’re published? ⁠⁠Subscribe⁠⁠ to Career Insider for our job market updates, job trends, career advice and more.

en

00:29:25

Shutdown Pauses New Drug Reviews, CDC Issues New...

BioSpace ·

2025/10/08

The U.S. government is now in its second week of a shutdown—with the FDA having paused acceptance of all new drug applications for the duration. But it was business as usual at the CDC, which adopted the recent recommendations of its newly revamped advisory committee on chickenpox and COVID-19 vaccines. And another senior leader, National Institute of Allergy and Infectious Diseases Director Jeanne Marrazzo, was fired last week, after filing a whistleblower report. Across the country, cell and gene

en

00:18:30

Hit Me With Your Best Shot: Understanding...

BioSpace ·

2025/10/02

Clinical trials can present many challenges for patients–particularly injections.Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, discuss nuance, challenges and opportunities of autoinjectors and combination drug delivery systems.Additionally, they advocate that drug delivery systems enter the conversation earlier in clinical development stages given interdependencies. This episode is presented in partnership with PII.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori

en

00:22:25

M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal...

BioSpace ·

2025/10/01

Genmab closed out a busy third quarter for M&A in biopharma, picking up cancer biotech Merus for $8 billion. This deal—the year’s fifth largest—came just a week after Pfizer acquired rising obesity star Metsera for $4.9 billion. Just seven days later, Metsera made the New York–based pharma look like a genius with mid-stage data for one of the deal’s centerpiece therapies, MET-097i, showing 14% placebo-adjusted weight loss over 28 weeks.After months of tarrying and threats, President Donald Trump

en

00:32:12

FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid,...

BioSpace ·

2025/09/24

The FDA is working to reapprove GSK’s long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developmental delays with autistic features.” This immediately followed a much-anticipated press conference in which President Donald Trump, flanked by Health Secretary Robert F. Kennedy Jr and other healthcare administrators, linked the use of Tylenol during pregnancy to rising rates of autism. Meanwhile, Pfizer woke us all up Monday with the news that it had

en

00:22:20

What Do AI and Hammers Have in Common?

BioSpace ·

2025/09/18

In this episode, Lori Ellis and Colin Zick spend a little time further discussing some of the points brought up in the Bioprocessing Summit last month. AI is a tool, a powerful one but a tool. Understanding this, they explore the connections between hammers, AI, The Planet of the Apes and monoliths.In the end, it is all about compliance.Host⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestColin Zick, Partner, Foley Hoag LLP Disclaimer: The views expressed in this discussion by guests are

en

00:27:02

China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip...

BioSpace ·

2025/09/17

A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. from China, and pharma companies exit the U.K. in droves. President Donald Trump is reportedly writing an executive order that would clamp down on the pharmaceutical industry’s ability to buy new molecules from biotechs based in China, while Sanofi, Merck and more have canceled or suspended investments in the U.K. following a sizeable increase in a

en

00:32:05

Unpacking the Latest MAHA Report, RFK’s Senate...

BioSpace ·

2025/09/10

The Make America Healthy Again Commission released itssecond report Tuesday, recommending, among other efforts, an investigation into a possible link between vaccines and the uptick in chronic disease. At a livestreamed MAHA commission meeting, Health Secretary Robert F. Kennedy painted a dire picture of the country’s health, saying the U.S. now has “the highest chronic disease burden of any country in the world.” Looking back to last week, all eyes were on HealthSecretary Robert F. Kennedy Jr.’s

en

00:17:08

The 'Research Safety Net' Saving Scientists from...

BioSpace ·

2025/09/04

In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment. He explains that investors now demand more robust translational data showing real potential to impact human health, rather than just basic in vitro results, forcing researchers to generate better evidence packages earlier in development.This episode is presented in partnership with ⁠⁠Taconic

en

00:31:29

CDC Faces Critical Meetings Amid COVID Vaccine...

BioSpace ·

2025/09/03

We returned from the Labor Day holiday to a spate of intriguing deals, including two that could surpass $2 billion: Vertex’s new pact with Enlaza for autoimmune disease—which the Casgevy maker hopes could ease conditioning for the sickle cell/beta thalassemia gene therapy—and Novartis’ agreement with Arrowhead for neurodegenerative diseases such as Parkinson’s. But as we look ahead, Thursday’s Senate Finance Committee will be the focus this week, as Health and Human Services Secretary Robert F

en

00:22:40

Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on...

BioSpace ·

2025/08/27

Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to head to the FDA with a new drug application. For more in-depth discussion on the oral weight-loss space, check out a special episode of The Weekly. And stay tuned to BioSpace for more unique coverage of this market as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland. On

en

179 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter